1. Cheng TJ, Ke DS, Guo HR. The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan.
Water Res 2010;44:5770-5776.
3. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Lancet Neurol 2009;8:1095-1102.
4. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med 1995;333:1581-1587.
5. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, et al. Get with the guidelines-stroke performance indicators: surveillance of stroke care in the Taiwan stroke registry: get with the guidelines-stroke in Taiwan.
Circulation 2010;122:1116-1123.
6. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, et al. Get with the guidelines-stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.
Circulation 2009;119:107-115.
7. Lattimore SU, Chalela J, Davis L, DeGraba T, Ezzeddine M, Haymore J, et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.
Stroke 2003;34:e55-e57.
9. Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition.
Stroke 2011;42:2651-2665.
10. Meretoja A, Roine RO, Kaste M, Linna M, Roine S, Juntunen M, et al. Effectiveness of primary and comprehensive stroke centers: PERFECT stroke: a nationwide observational study from Finland.
Stroke 2010;41:1102-1107.
11. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
Stroke 2008;39:924-928.
12. Kleindorfer D, de los Rios La Rosa F, Khatri P, Kissela B, Mackey J, et al. Temporal trends in acute stroke management.
Stroke 2013;44(6 Suppl 1):S129-S131.
13. Lindsberg PJ, Häppölä O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment.
Neurology 2006;67:334-336.
14. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
JAMA 2013;309:2480-2488.
15. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
Lancet 2012;379:2364-2372.
16. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
JAMA 2000;283:1145-1150.
17. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
JAMA 2000;283:1151-1158.
18. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke 2013;44:870-947.
19. Chang KC, Tseng MC, Tan TY. Prehospital delay after acute stroke in Kaohsiung, Taiwan.
Stroke 2004;35:700-704.
20. Hsieh CY, Chen WF, Chen CH, Wang CY, Chen CJ, Lai EC, et al. Efforts to reduce the door-to-needle time of thrombolysis in acute ischemic stroke: video-assisted therapeutic risk communication.
J Formos Med Assoc 2014;113:929-933.
21. Sung YF, Lee JT, Tsai CL, Lin CC, Hsu YD, Lin JC, et al. Risk factor stratification for intracranial stenosis in Taiwanese patients with cervicocerebral stenosis.
J Am Heart Assoc 2015;4:e002692.
22. Sung YF, Lu CC, Lee JT, Hung YJ, Hu CJ, Jeng JS, et al. Homozygous ALDH2*2 is an independent risk factor for ischemic stroke in Taiwanese men.
Stroke 2016;47:2174-2179.